drugset

drugset / Trial / NCT01500850

Establishing Cardiovascular Biomarkers to Define Preferred Lantus® Use

NCT01500850 ↗

Phase 4 Unknown 60 enrolled ikfe-CRO GmbH IKFE Institute for Clinical Research and Development · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

The aim of this study is to observe changes in cardiovascular biomarkers during treatment with Lantus in patients with Type 2 Diabetes mellitus.

Timeline

Start: 2011-10
Primary completion: 2012-10
Completion: 2012-10

Publications

Semlitsch T, Engler J, Siebenhofer A, Jeitler K, Berghold A, Horvath K. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2020 Nov 9;11(11):CD005613. doi: 10.1002/14651858.CD005613.pub4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Insulin	Protein / enzyme biologic	—	—
Subject	Insulin glulisine	Protein / enzyme biologic	—	—
Subject	insulin glargine	Protein / enzyme biologic	—	—

Indications